Advancing Targeted Therapies for Rare Diseases Act of 2016

To allow the sponsor of an application for the approval of a targeted drug to rely upon data and information with respect to such sponsor's previously approved targeted drugs. 1. Short title This Act may be cited as the Advancing Targeted Therapies for Rare Diseases Act of 2015 2. Targeted drugs for rare diseases Title V of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 351 et seq. 506G. Targeted drugs for rare diseases (a) Purpose The purpose of this section, through the approach provided for in subsection (b), is to— (1) facilitate the development, review, and approval of genetically targeted drugs to address an unmet medical need in one or more patient subgroups (or gene variant subpopulations) with respect to rare diseases or conditions that are serious or life-threatening; and (2) maximize the use of scientific tools or methods, including surrogate endpoints and other biomarkers for such purposes. (b) Leveraging of data from previously approved drug application or applications The Secretary may, consistent with applicable standards for approval under this Act or section 351 of the Public Health Service Act, allow the sponsor of a genetically targeted drug to rely upon data and information— (1) previously developed by the same sponsor (or another sponsor that has provided the sponsor with a contractual right of reference to such data and information); and (2) submitted by a sponsor described in paragraph (1) in support of one or more applications previously approved under this Act or section 351 of the Public Health Service Act, for a drug that incorporates or utilizes the same or similar genetically targeted technology, or the same variant protein targeted technology, as the drug or drugs that are the subject of an application or applications described in paragraph (2). (c) Definitions For purposes of this section— (1) the term genetically targeted drug (A) is the subject of an application under section 505(b)(1) of this Act or section 351(a) of the Public Health Service Act for the treatment of a rare disease or condition (as such term is defined in section 526) that is serious or life-threatening; (B) incorporates or utilizes a genetically targeted technology or a variant protein targeted technology; and (C) may result in the modulation (including suppression, up-regulation, or activation) of the function of a gene or its associated gene product; (2) the term genetically targeted technology (3) the term variant protein targeted technology (d) Rule of construction Nothing in this section shall be construed to— (1) alter the authority of the Secretary to approve drugs pursuant to this Act or section 351 of the Public Health Service Act (as authorized prior to the date of enactment of the Advancing Targeted Therapies for Rare Diseases Act of 2015 (2) confer any new rights, beyond those authorized under this section, with respect to the permissibility of referencing information contained in another application submitted under section 505(b)(1) of this Act or section 351(a) of the Public Health Service Act. . 1. Short title This Act may be cited as the Advancing Targeted Therapies for Rare Diseases Act of 2016 2. Targeted drugs for rare diseases Subchapter B of chapter V of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360aa et seq. 529A. Targeted drugs for rare diseases (a) Purpose The purpose of this section, through the approach provided for in subsection (b), is to— (1) facilitate the development, review, and approval of genetically targeted drugs and variant protein targeted drugs to address an unmet medical need in one or more patient subgroups, including subgroups of patients with different mutations of a gene, with respect to rare diseases or conditions that are serious or life-threatening; and (2) maximize the use of scientific tools or methods, including surrogate endpoints and other biomarkers for such purposes. (b) Leveraging of data from previously approved drug application or applications The Secretary may, consistent with applicable standards for approval under this Act or section 351(a) of the Public Health Service Act, allow the sponsor of an application under section 505(b)(1) of this Act or section 351(a) of the Public Health Service Act for a genetically targeted drug or a variant protein targeted drug to rely upon data and information— (1) previously developed by the same sponsor (or another sponsor that has provided the sponsor with a contractual right of reference to such data and information); and (2) submitted by a sponsor described in paragraph (1) in support of one or more previously approved applications that were submitted under section 505(b)(1) of this this Act or section 351(a) of the Public Health Service Act, for a drug that incorporates or utilizes the same or similar genetically targeted technology as the drug or drugs that are the subject of an application or applications described in paragraph (2) or for a variant protein targeted drug that is the same or incorporates or utilizes the same variant protein targeted drug, as the drug or drugs that are the subject of an application or applications described in paragraph (2). (c) Definitions For purposes of this section— (1) the term genetically targeted drug (A) is the subject of an application under section 505(b)(1) of this Act or section 351(a) of the Public Health Service Act for the treatment of a rare disease or condition (as such term is defined in section 526) that is serious or life-threatening; (B) may result in the modulation (including suppression, up-regulation, or activation) of the function of a gene or its associated gene product; and (C) incorporates or utilizes a genetically targeted technology; (2) the term genetically targeted technology (3) the term variant protein targeted drug (A) is the subject of an application under section 505(b)(1) of this Act or section 351(a) of the Public Health Service Act for the treatment of a rare disease or condition (as such term is defined in section 526) that is serious or life-threatening; (B) modulates the function of a product of a mutated gene where such mutation is responsible in whole or in part for a given disease or condition; and (C) is intended to treat one or more patient subgroups, including subgroups of patients with different mutations of a gene, with the same disease or condition. (d) Rule of construction Nothing in this section shall be construed to— (1) alter the authority of the Secretary to approve drugs pursuant to this Act or section 351 of the Public Health Service Act (as authorized prior to the date of enactment of this section), including the standards of evidence, and applicable conditions, for approval under such applicable Act; or (2) confer any rights, beyond those authorized under this Act or the Public Health Service Act prior to enactment of this section, with respect to the permissibility of referencing information contained in another application submitted under section 505(b)(1) of this Act or section 351(a) of the Public Health Service Act. . April 5, 2016 Reported with an amendment

Summary: Advancing Targeted Therapies for Rare Diseases Act of 2016 (Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to permit the Food and Drug Administration to allow the sponsor of a new drug or biological product for the treatment of a rare, serious condition to rely upon information submitted for an approved medication that uses the same technology. For a sponsor to be eligible to rely upon submitted information: (1) the sponsor must have developed, or have a right of reference to, the relied upon information; and (2) the new medication must use nucleic acids (e.g., DNA) or similar chemicals, or must affect a disease-causing product of a mutated gene (e.g., the protein that causes cystic fibrosis).